Who are CHF 5993 200/6/12.5 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FF/UMEC/VI, GFF MDI, Triple FF/UMEC/VI, FF/UMEC/VI (100/62.5/25) mcg, BGF MDI (PT010).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf-5993-200-6-12-5-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CHF 5993 200/6/12.5 µg — Competitive Intelligence Brief

CHF 5993 200/6/12.5 µg (CHF 5993 200/6/12.5 µg) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA). Area: Respiratory/Pulmonology.

phase 3 Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

CHF 5993 200/6/12.5 µg (CHF 5993 200/6/12.5 µg) — Chiesi Farmaceutici S.p.A.. CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CHF 5993 200/6/12.5 µg TARGET	CHF 5993 200/6/12.5 µg	Chiesi Farmaceutici S.p.A.	phase 3	Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI	FF/UMEC/VI	Dr. Grace Parraga	marketed	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
GFF MDI	GFF MDI	Pearl Therapeutics, Inc.	phase 3	Combination inhaled corticosteroid / long-acting beta-2 agonist / long-acting muscarinic antagonist	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
Triple FF/UMEC/VI	Triple FF/UMEC/VI	GlaxoSmithKline	phase 3	ICS/LAMA/LABA combination	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI (100/62.5/25) mcg	FF/UMEC/VI (100/62.5/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
BGF MDI (PT010)	BGF MDI (PT010)	Pearl Therapeutics, Inc.	phase 3	Triple-combination inhaler (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF 5993 200/6/12.5 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/chf-5993-200-6-12-5-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab